DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Methylene blue |
DMJAPE7
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Methylene blue. |
Acquired methaemoglobinaemia [3A93]
|
[10] |
Ivosidenib |
DM8S6T7
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[11] |
Midostaurin |
DMI6E0R
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Idarubicin |
DMM0XGL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Daunorubicin |
DMQUSBT
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Arn-509 |
DMT81LZ
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Arn-509. |
Acute myeloid leukaemia [2A60]
|
[12] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[13] |
Oliceridine |
DM6MDCF
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Oliceridine. |
Acute pain [MG31]
|
[10] |
Tacrine |
DM51FY6
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Tacrine. |
Alzheimer disease [8A20]
|
[10] |
Galantamine |
DMEO794
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Galantamine. |
Alzheimer disease [8A20]
|
[10] |
Rivastigmine |
DMG629M
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Rivastigmine. |
Alzheimer disease [8A20]
|
[10] |
Metronidazole |
DMTIVEN
|
Minor |
Increased risk of prolong QT interval by the combination of Palonosetron and Metronidazole. |
Amoebiasis [1A36]
|
[14] |
Ivabradine |
DM0L594
|
Major |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Ivabradine. |
Angina pectoris [BA40]
|
[12] |
Bepridil |
DM0RKS4
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Bepridil. |
Angina pectoris [BA40]
|
[10] |
Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[15] |
Promazine |
DMZAL7W
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Promazine. |
Appearance/behaviour symptom [MB23]
|
[10] |
Cilostazol |
DMZMSCT
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Cilostazol. |
Arterial occlusive disease [BD40]
|
[10] |
Voriconazole |
DMAOL2S
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Voriconazole. |
Aspergillosis [1F20]
|
[10] |
Posaconazole |
DMUL5EW
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Posaconazole. |
Aspergillosis [1F20]
|
[10] |
Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Levalbuterol. |
Asthma [CA23]
|
[16] |
Terbutaline |
DMD4381
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Terbutaline. |
Asthma [CA23]
|
[17] |
Pirbuterol |
DMI5678
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Pirbuterol. |
Asthma [CA23]
|
[17] |
Salbutamol |
DMN9CWF
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Salbutamol. |
Asthma [CA23]
|
[16] |
Formoterol |
DMSOURV
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Formoterol. |
Asthma [CA23]
|
[17] |
Lisdexamfetamine |
DM6W8V5
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[12] |
Desipramine |
DMT2FDC
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Desipramine. |
Attention deficit hyperactivity disorder [6A05]
|
[10] |
Ofloxacin |
DM0VQN3
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Ciprofloxacin XR |
DM2NLS9
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Ciprofloxacin XR. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Clarithromycin |
DM4M1SG
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Clarithromycin. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Sulfamethoxazole |
DMB08GE
|
Minor |
Increased risk of prolong QT interval by the combination of Palonosetron and Sulfamethoxazole. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Sparfloxacin |
DMB4HCT
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Sparfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Linezolid |
DMGFPU2
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Gemifloxacin |
DMHT34O
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Norfloxacin |
DMIZ6W2
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Levofloxacin |
DMS60RB
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Lomefloxacin |
DMVRH9C
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Lomefloxacin. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Telithromycin |
DMZ4P3A
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Telithromycin. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Retigabine. |
Behcet disease [4A62]
|
[10] |
Loperamide |
DMOJZQ9
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Loperamide. |
Bowel habit change [ME05]
|
[19] |
Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[10] |
Lapatinib |
DM3BH1Y
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Lapatinib. |
Breast cancer [2C60-2C6Y]
|
[10] |
Tamoxifen |
DMLB0EZ
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Tamoxifen. |
Breast cancer [2C60-2C6Y]
|
[10] |
Toremifene |
DMQYUWG
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Toremifene. |
Breast cancer [2C60-2C6Y]
|
[10] |
Bosutinib |
DMTI8YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[12] |
Sotalol |
DML60TN
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Sotalol. |
Cardiac arrhythmia [BC9Z]
|
[10] |
PF-04449913 |
DMSB068
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[20] |
Olodaterol |
DM62B78
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[17] |
Vilanterol |
DMF5EK1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Vilanterol. |
Chronic obstructive pulmonary disease [CA22]
|
[16] |
Salmeterol |
DMIEU69
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Salmeterol. |
Chronic obstructive pulmonary disease [CA22]
|
[17] |
Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[17] |
Arformoterol |
DMYM974
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[17] |
Dihydrocodeine |
DMB0FWL
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Dihydrocodeine. |
Chronic pain [MG30]
|
[21] |
Levomilnacipran |
DMV26S8
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Levomilnacipran. |
Chronic pain [MG30]
|
[10] |
Oxaliplatin |
DMQNWRD
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Oxaliplatin. |
Colorectal cancer [2B91]
|
[10] |
Isoproterenol |
DMK7MEY
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Isoproterenol. |
Conduction disorder [BC63]
|
[16] |
Halothane |
DM80OZ5
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Halothane. |
Corneal disease [9A76-9A78]
|
[10] |
Propofol |
DMB4OLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Propofol. |
Corneal disease [9A76-9A78]
|
[22] |
Sevoflurane |
DMC9O43
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Sevoflurane. |
Corneal disease [9A76-9A78]
|
[10] |
Alfentanil |
DMVO0UB
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Alfentanil. |
Corneal disease [9A76-9A78]
|
[10] |
Probucol |
DMVZQ2M
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Probucol. |
Coronary atherosclerosis [BA80]
|
[10] |
Dextromethorphan |
DMUDJZM
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Dextromethorphan. |
Cough [MD12]
|
[10] |
Clofazimine |
DMEBOFW
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Clofazimine. |
Crohn disease [DD70]
|
[23] |
Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Pasireotide. |
Cushing syndrome [5A70]
|
[10] |
Osilodrostat |
DMIJC9X
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Osilodrostat. |
Cushing syndrome [5A70]
|
[12] |
Trimipramine |
DM1SC8M
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Trimipramine. |
Depression [6A70-6A7Z]
|
[10] |
Imipramine |
DM2NUH3
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Imipramine. |
Depression [6A70-6A7Z]
|
[10] |
Nortriptyline |
DM4KDYJ
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Nortriptyline. |
Depression [6A70-6A7Z]
|
[10] |
Nefazodone |
DM4ZS8M
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Nefazodone. |
Depression [6A70-6A7Z]
|
[10] |
Paroxetine |
DM5PVQE
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Paroxetine. |
Depression [6A70-6A7Z]
|
[10] |
Vortioxetine |
DM6F1PU
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Vortioxetine. |
Depression [6A70-6A7Z]
|
[10] |
Duloxetine |
DM9BI7M
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Duloxetine. |
Depression [6A70-6A7Z]
|
[10] |
Isocarboxazid |
DMAF1NB
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Isocarboxazid. |
Depression [6A70-6A7Z]
|
[10] |
Milnacipran |
DMBFE74
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Milnacipran. |
Depression [6A70-6A7Z]
|
[10] |
Escitalopram |
DMFK9HG
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Escitalopram. |
Depression [6A70-6A7Z]
|
[10] |
Tranylcypromine |
DMGB5RE
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Tranylcypromine. |
Depression [6A70-6A7Z]
|
[10] |
Desvenlafaxine |
DMHD4PE
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Desvenlafaxine. |
Depression [6A70-6A7Z]
|
[10] |
Phenelzine |
DMHIDUE
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Phenelzine. |
Depression [6A70-6A7Z]
|
[10] |
Clomipramine |
DMINRKW
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Clomipramine. |
Depression [6A70-6A7Z]
|
[10] |
Trazodone |
DMK1GBJ
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Trazodone. |
Depression [6A70-6A7Z]
|
[10] |
Amoxapine |
DMKITQE
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Amoxapine. |
Depression [6A70-6A7Z]
|
[10] |
Doxepin |
DMPI98T
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Doxepin. |
Depression [6A70-6A7Z]
|
[14] |
Maprotiline |
DMPWB7T
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Maprotiline. |
Depression [6A70-6A7Z]
|
[10] |
5-hydroxy-L-tryptophan |
DMDWZGJ
|
Major |
Additive serotonergic effects by the combination of Palonosetron and 5-hydroxy-L-tryptophan. |
Discovery agent [N.A.]
|
[14] |
Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[10] |
Ingrezza |
DMVPLNC
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Ingrezza. |
Dystonic disorder [8A02]
|
[24] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Palonosetron caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[25] |
Solifenacin |
DMG592Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Solifenacin. |
Functional bladder disorder [GC50]
|
[10] |
Pentamidine |
DMHZJCG
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Pentamidine. |
Fungal infection [1F29-1F2F]
|
[10] |
Ketoconazole |
DMPZI3Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[10] |
Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[10] |
Procarbazine |
DMIK367
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Procarbazine. |
Hodgkin lymphoma [2B30]
|
[10] |
Fostemsavir |
DM50ILT
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[26] |
Efavirenz |
DMC0GSJ
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Efavirenz. |
Human immunodeficiency virus disease [1C60-1C62]
|
[27] |
Saquinavir |
DMG814N
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Saquinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[28] |
Lopinavir |
DMITQS0
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Lopinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[10] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[10] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[12] |
Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[10] |
Crizotinib |
DM4F29C
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Crizotinib. |
Lung cancer [2C25]
|
[29] |
Ceritinib |
DMB920Z
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Ceritinib. |
Lung cancer [2C25]
|
[10] |
Osimertinib |
DMRJLAT
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Osimertinib. |
Lung cancer [2C25]
|
[30] |
Selpercatinib |
DMZR15V
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Selpercatinib. |
Lung cancer [2C25]
|
[12] |
Lumefantrine |
DM29GAD
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Lumefantrine. |
Malaria [1F40-1F45]
|
[14] |
Halofantrine |
DMOMK1V
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Halofantrine. |
Malaria [1F40-1F45]
|
[31] |
Chloroquine |
DMSI5CB
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Chloroquine. |
Malaria [1F40-1F45]
|
[32] |
Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[32] |
Quinine |
DMSWYF5
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Quinine. |
Malaria [1F40-1F45]
|
[10] |
Primaquine |
DMWQ16I
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Primaquine. |
Malaria [1F40-1F45]
|
[10] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[12] |
Arsenic trioxide |
DM61TA4
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Arsenic trioxide. |
Mature B-cell lymphoma [2A85]
|
[33] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Vemurafenib. |
Melanoma [2C30]
|
[10] |
LGX818 |
DMNQXV8
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and LGX818. |
Melanoma [2C30]
|
[34] |
Almogran |
DM7I64Z
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Almogran. |
Migraine [8A80]
|
[10] |
Frovatriptan |
DM7RE8P
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Frovatriptan. |
Migraine [8A80]
|
[10] |
Rizatriptan |
DMDJMA3
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Rizatriptan. |
Migraine [8A80]
|
[10] |
Naratriptan |
DMO50U2
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Naratriptan. |
Migraine [8A80]
|
[10] |
Sumatriptan |
DMVYXR8
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Sumatriptan. |
Migraine [8A80]
|
[10] |
Lasmiditan |
DMXLVDT
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Lasmiditan. |
Migraine [8A80]
|
[10] |
Panobinostat |
DM58WKG
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Panobinostat. |
Multiple myeloma [2A83]
|
[35] |
Thalidomide |
DM70BU5
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Thalidomide. |
Multiple myeloma [2A83]
|
[14] |
Siponimod |
DM2R86O
|
Major |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Siponimod. |
Multiple sclerosis [8A40]
|
[14] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Fingolimod. |
Multiple sclerosis [8A40]
|
[10] |
Romidepsin |
DMT5GNL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Romidepsin. |
Mycosis fungoides [2B01]
|
[10] |
Nilotinib |
DM7HXWT
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Dasatinib |
DMJV2EK
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[36] |
Bupropion |
DM5PCS7
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Bupropion. |
Nicotine use disorder [6C4A]
|
[10] |
Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[14] |
Sibutramine |
DMFJTDI
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Sibutramine. |
Obesity [5B80-5B81]
|
[10] |
Dexfenfluramine |
DMJ7YDS
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Dexfenfluramine. |
Obesity [5B80-5B81]
|
[10] |
Levomethadyl Acetate |
DM06HG5
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Levomethadyl Acetate. |
Opioid use disorder [6C43]
|
[12] |
Lofexidine |
DM1WXA6
|
Moderate |
Additive hypotensive effects by the combination of Palonosetron and Lofexidine. |
Opioid use disorder [6C43]
|
[10] |
Rucaparib |
DM9PVX8
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Rucaparib. |
Ovarian cancer [2C73]
|
[10] |
Pentazocine |
DM1XBHS
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Pentazocine. |
Pain [MG30-MG3Z]
|
[10] |
Dextropropoxyphene |
DM23HCX
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Dextropropoxyphene. |
Pain [MG30-MG3Z]
|
[37] |
Butorphanol |
DM5KYPJ
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Butorphanol. |
Pain [MG30-MG3Z]
|
[21] |
Oxymorphone |
DM65AGJ
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Oxymorphone. |
Pain [MG30-MG3Z]
|
[21] |
Levorphanol |
DMGS80V
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Levorphanol. |
Pain [MG30-MG3Z]
|
[21] |
Dezocine |
DMJDB0Y
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Dezocine. |
Pain [MG30-MG3Z]
|
[21] |
Nalbuphine |
DMOSQGU
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Nalbuphine. |
Pain [MG30-MG3Z]
|
[21] |
Buprenorphine |
DMPRI8G
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Buprenorphine. |
Pain [MG30-MG3Z]
|
[10] |
Hydrocodone |
DMQ2JO5
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Hydrocodone. |
Pain [MG30-MG3Z]
|
[21] |
Meperidine |
DMX4GND
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Meperidine. |
Pain [MG30-MG3Z]
|
[10] |
Oxycodone |
DMXLKHV
|
Moderate |
Additive serotonergic effects by the combination of Palonosetron and Oxycodone. |
Pain [MG30-MG3Z]
|
[21] |
Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[10] |
Pimavanserin |
DMR7IVC
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Pimavanserin. |
Parkinsonism [8A00]
|
[38] |
Famotidine |
DMRL3AB
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Famotidine. |
Peptic ulcer [DA61]
|
[14] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[39] |
Lefamulin |
DME6G97
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Lefamulin. |
Pneumonia [CA40]
|
[40] |
Ritodrine |
DM4V6RL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Ritodrine. |
Preterm labour/delivery [JB00]
|
[17] |
ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and ABIRATERONE. |
Prostate cancer [2C82]
|
[12] |
Nilutamide |
DMFN07X
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Nilutamide. |
Prostate cancer [2C82]
|
[12] |
Enzalutamide |
DMGL19D
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Enzalutamide. |
Prostate cancer [2C82]
|
[12] |
Flutamide |
DMK0O7U
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Flutamide. |
Prostate cancer [2C82]
|
[12] |
Relugolix |
DMK7IWL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Relugolix. |
Prostate cancer [2C82]
|
[12] |
Bicalutamide |
DMZMSPF
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Bicalutamide. |
Prostate cancer [2C82]
|
[12] |
Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[10] |
Fluphenazine |
DMIT8LX
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Fluphenazine. |
Psychotic disorder [6A20-6A25]
|
[10] |
Triflupromazine |
DMKFQJP
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Triflupromazine. |
Psychotic disorder [6A20-6A25]
|
[10] |
Sorafenib |
DMS8IFC
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Sorafenib. |
Renal cell carcinoma [2C90]
|
[10] |
Gatifloxacin |
DMSL679
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[41] |
Quetiapine |
DM1N62C
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Quetiapine. |
Schizophrenia [6A20]
|
[10] |
Mesoridazine |
DM2ZGAN
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Mesoridazine. |
Schizophrenia [6A20]
|
[10] |
Thioridazine |
DM35M8J
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Thioridazine. |
Schizophrenia [6A20]
|
[10] |
Aripiprazole |
DM3NUMH
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Aripiprazole. |
Schizophrenia [6A20]
|
[14] |
Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Iloperidone. |
Schizophrenia [6A20]
|
[10] |
Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Paliperidone. |
Schizophrenia [6A20]
|
[10] |
Haloperidol |
DM96SE0
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Haloperidol. |
Schizophrenia [6A20]
|
[10] |
Perphenazine |
DMA4MRX
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Perphenazine. |
Schizophrenia [6A20]
|
[10] |
Chlorpromazine |
DMBGZI3
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Chlorpromazine. |
Schizophrenia [6A20]
|
[10] |
Trifluoperazine |
DMKBYWI
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Trifluoperazine. |
Schizophrenia [6A20]
|
[10] |
Risperidone |
DMN6DXL
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Risperidone. |
Schizophrenia [6A20]
|
[10] |
Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Amisulpride. |
Schizophrenia [6A20]
|
[42] |
Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Asenapine. |
Schizophrenia [6A20]
|
[10] |
Pimozide |
DMW83TP
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Pimozide. |
Schizophrenia [6A20]
|
[12] |
Fentanyl |
DM8WAHT
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Fentanyl. |
Sensation disturbance [MB40]
|
[10] |
Sufentanil |
DMU7YEL
|
Major |
Additive serotonergic effects by the combination of Palonosetron and Sufentanil. |
Sensation disturbance [MB40]
|
[10] |
Vardenafil |
DMTBGW8
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Vardenafil. |
Sexual dysfunction [HA00-HA01]
|
[10] |
Epirubicin |
DMPDW6T
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Vandetanib |
DMRICNP
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Doxorubicin |
DMVP5YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Pitolisant. |
Somnolence [MG42]
|
[10] |
Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[10] |
Adenosine |
DMM2NSK
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Palonosetron and Adenosine. |
Supraventricular tachyarrhythmia [BC81]
|
[10] |
Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Lenvatinib. |
Thyroid cancer [2D10]
|
[10] |
Cabozantinib |
DMIYDT4
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Cabozantinib. |
Thyroid cancer [2D10]
|
[12] |
Papaverine |
DMCA9QP
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Papaverine. |
Tonus and reflex abnormality [MB47]
|
[43] |
Tizanidine |
DMR2IQ4
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Tizanidine. |
Tonus and reflex abnormality [MB47]
|
[10] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Tacrolimus. |
Transplant rejection [NE84]
|
[10] |
Astemizole |
DM2HN6Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Astemizole. |
Vasomotor/allergic rhinitis [CA08]
|
[10] |
Trimeprazine |
DMEMV9D
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Trimeprazine. |
Vasomotor/allergic rhinitis [CA08]
|
[37] |
Procainamide |
DMNMXR8
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Procainamide. |
Ventricular tachyarrhythmia [BC71]
|
[10] |
Propafenone |
DMPIBJK
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Propafenone. |
Ventricular tachyarrhythmia [BC71]
|
[10] |
Flecainide |
DMSQDLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Palonosetron and Flecainide. |
Ventricular tachyarrhythmia [BC71]
|
[10] |
Amiodarone |
DMUTEX3
|
Major |
Increased risk of prolong QT interval by the combination of Palonosetron and Amiodarone. |
Ventricular tachyarrhythmia [BC71]
|
[10] |
----------- |
|
|
|
|
|